Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Fharat A. Raja"'
Autor:
Jonathan A. Ledermann, Fharat A. Raja, Ann Marie Swart, Galina Velikova, Adrian Cook, Richard Kaplan, Julia Brown, Dan Stark, Wendi Qian, Michael Brundage, Andrew C. Embleton
Publikováno v:
Cancer. 123:2752-2761
BACKGROUND: The ICON6 trial showed that cediranib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, improved clinical outcomes for patients with platinum-sensitive relapsed ovarian cancer when it was used with chemothera
Autor:
Jane Brown, Roshan Agarwal, Catherine Harper-Wynne, A. Humphreys, Eliot Sims, Peter Hall, Mukesh Mukesh, Sundus Yahya, Nawaz Walji, Mojca Persic, Donna L. Howe, Simon Waters, Wendy Taylor, Anita Chhabra, Karen Tipples, Helen Innes, Mark Churn, Peter Ostler, Pamela Woodings, Helen Roe, Lisa H Barraclough, Shrushma Loi, Maggie Wilcox, Susan Lupton, Adrian Harnett, Rebecca Bowen, Peter Simmonds, Natasha Mithal, H. M. Earl, Apurna Jegannathen, Kathryn Wright, A.S. Dhadda, Rozenn Allerton, Jean Abraham, Karen McAdam, Ioannis Gounaris, Mohini Varughese, Mark Harries, Helen Neville-Webbe, Catherine Bale, Narottam Thanvi, Carolyn Bedi, Carlos Caldas, Fharat A. Raja, Helena M. Earl, David Miles, Trevor McGolick, Andrew D. Goodman, Kerry Raynes, Anthony Neal, Richard Simcock, Hartmut Kristeleit, Carol MacGregor, Christopher McCabe, Caroline Archer, Laura Pettit, Chris Bradley, Anne-Laure Vallier, Urmila Barthakur, Perric Crellin, S O'Reilly, Betania Mahler Araujo, Andrew Eichholz, Louise Hiller, Anne Rigg, Janine Mansi, Jacqueline Newby, Janet A. Dunn, Sarah Smith, Chris Plummer, Jennifer Marshall, Aian Moss, Zafar Malik, Larry Hayward, Mohammad Butt, Andrew M Wardley, Anup Vinayan, Shiroma De Silva-Minor, Mei-Lin Ah-See, Sue Down, Helen B Higgins, Catherine Reed, Kim Benstead, Rakesh Mehra, Luke Hughes-Davies, David Cameron, Daniel Nelmes, O.S. Din, Charlotte Moss, Daniel Epurescu, Anne C Armstrong, Nicola Storey, David J. Eaton, Hafiz Algurafi, Mariam Jafri, Daniel Rea, Nihal Shah, Elena Provenzano, Susan Cleator, Muireann Kelleher, Claire Hulme, Daniela Lee, D. Bloomfield, Margaret Daly, Joanne Cliff, Chee Goh, Sanjay Raj, Maher Hadaki, Jayant S. Vaidya, Robert Grieve
Publikováno v:
Earl, H M, Hiller, L, Vallier, A-L, Loi, S, McAdam, K, Hughes-Davies, L, Harnett, A N, Ah-See, M-L, Simcock, R, Rea, D, Raj, S, Woodings, P, Harries, M, Howe, D, Raynes, K, Higgins, H B, Wilcox, M, Plummer, C, Mansi, J, Gounaris, I, Mahler-Araujo, B, Provenzano, E, Chhabra, A, Abraham, J E, Caldas, C, Hall, P S, McCabe, C, Hulme, C, Miles, D, M Wardley, A & Cameron, D A & Dunn, J A 2019, ' 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial ', The Lancet, vol. 393, no. 10191, pp. 2599-2612 . https://doi.org/10.1016/S0140-6736(19)30650-6
Lancet (London, England)
Lancet (London, England)
Background: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter treatment could provide similar efficacy while reducing toxicities and cost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd37138df2c42b14428f44dc7b4ec95b
http://wrap.warwick.ac.uk/118352/2/WRAP-6-versus-12-months-adjuvant-trastuzumab-HER2-positive-early-breast-cancer(PERSEPHONE)-Dunn-2019.pdf
http://wrap.warwick.ac.uk/118352/2/WRAP-6-versus-12-months-adjuvant-trastuzumab-HER2-positive-early-breast-cancer(PERSEPHONE)-Dunn-2019.pdf
Autor:
Fharat A. Raja, Tim Mould, Andrea Milani, Allan Hackshaw, Nicola MacDonald, Martin Widschwendter, Mary McCormack, Adeola Olatain, Jonathan A. Ledermann, Rebecca Kristeleit, Daniela Luvero
Publikováno v:
ESMO Open
Background Current standard neoadjuvant treatment for advanced ovarian cancer is 3-weekly platinum-based chemotherapy (CP3w). Patients unable to have interval debulking surgery (IDS) or with significant residual disease have a poor outcome to CP3w tr
Autor:
Iftekhar Khan, Lee C. Webber, L Dawson-Athey, M. Persic, Stan B. Kaye, A Feeney, LE James, Andrew R Clamp, Fharat A. Raja, Jonathan A. Ledermann, Iain A. McNeish, Rebecca Kristeleit, Marcia Hall, Saikat Banerjee, C Lawrence, Geoffrey Hall, Helena M. Earl
Publikováno v:
Annals of Oncology. 25:1988-1995
We investigated whether the Src inhibitor saracatinib (AZD0530) improved efficacy of weekly paclitaxel in platinum-resistant ovarian cancer.Patients with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer were randomised 2 : 1 to
Autor:
Dan P, Stark, Adrian, Cook, Julia M, Brown, Michael D, Brundage, Andrew C, Embleton, Richard S, Kaplan, Fharat A, Raja, Ann Marie W, Swart, Galina, Velikova, Wendi, Qian, Jonathan A, Ledermann
Publikováno v:
Cancer
BACKGROUND The ICON6 trial showed that cediranib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, improved clinical outcomes for patients with platinum‐sensitive relapsed ovarian cancer when it was used with chemother
Autor:
A. du Bois, M K B Parmar, Jonathan A. Ledermann, Antonio González-Martín, Nicoletta Colombo, Fharat A. Raja, Ignace Vergote, Nicholas Counsell, David S. Alberts, Valter Torri, Jacobus Pfisterer, Marie Plante
Publikováno v:
Annals of Oncology. 24:3028-3034
The majority of women with ovarian cancer develop recurrent disease. For patients with a platinum-free interval of >6 months, platinum-based chemotherapy is a treatment of choice. The benefit of platinum-based combination chemotherapy in randomized t
Autor:
Nicoletta Colombo, Cristiana Sessa, Fharat A. Raja, Antonio González-Martín, Jonathan A. Ledermann, Christina Fotopoulou
Publikováno v:
Annals of Oncology. 24:vi24-vi32
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up N. Colombo, M. Peiretti, G. Parma, M. Lapresa, R. Mancari, S. Carinelli, C. Sessa & M. Castiglione On behalf of the ES
Autor:
Laura Farrelly, Mahesh K.B. Parmar, Gordon J. S. Rustin, Richard Kaplan, Ann Marie Swart, Elizabeth Eisenhauer, Stan B. Kaye, Fharat A. Raja, Michael Friedlander, Dan Stark, Hal W. Hirte, Elizabeth Clark, Timothy J. Perren, Adrian Cook, Jonathan A. Ledermann, Andrew C. Embleton, Gordon C Jayson, Antonio González-Martín, Michelle D. Vaughan
SummaryBackgroundAngiogenesis is a validated clinical target in advanced epithelial ovarian cancer. Cediranib is an oral antiangiogenic vascular endothelial growth factor receptor 1–3 inhibitor that has shown antitumour activity in recurrent ovaria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6c728f51b9da1b574006964d10f7f81
https://ueaeprints.uea.ac.uk/id/eprint/58290/
https://ueaeprints.uea.ac.uk/id/eprint/58290/
Publikováno v:
Cancer Treatment Reviews. 38:662-672
The treatment of ovarian cancer remains challenging as the majority of patients will relapse and die from their disease despite successful first-line treatment. New treatment strategies are needed and recently there has been an explosion of new agent
Autor:
M K B Parmar, Wendi Qian, Fharat A. Raja, H Hirte, Clare L. Griffin, Ann Marie Swart, Jonathan A. Ledermann
Publikováno v:
British Journal of Cancer
Background: Cediranib is a potent oral vascular endothelial growth factor (VEGF) signalling inhibitor with activity against all three VEGF receptors. The International Collaboration for Ovarian Neoplasia 6 (ICON6) trial was initiated based on evidenc